- One of the largest private funding rounds by a healthtech company in Southeast Asia
- Fourth investment in Asia this year by Novo Holdings
- With a presence in six countries in the APAC region, Doctor Anywhere serves more than 1.5 million users
SINGAPORE – 31 August 2021 – Novo Holdings A/S (“Novo Holdings” and “NH”), a leading international investor in healthcare and life sciences, today announces that it has participated in the US$65.7 million Series C financing in Doctor Anywhere (“DA”, “the Company”), a regional tech-led healthcare company headquartered in Singapore. As a result of the financing, Dr Amit Kakar, Senior Partner, Head of Novo Holdings Equity Asia will join the Company’s Board of Directors and Carol Wang, Senior Associate, Novo Holdings Equity Asia will join the Board as an Observer.